<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nierengarten, Mary Beth</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Miller, David Scott</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ROMA or OVA1 Improves Identification and Treatment of Women with Ovarian Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">28-29</style></pages><abstract><style  face="normal" font="default" size="100%">Although it is well recognized that surgical staging improves survival in women with ovarian cancer, survival outcomes in these women remain low. According to 2007 Surveillance, Epidemiology, and End Results (SEER) data, 10-year survival rates for a woman with stage III and one with stage IV ovarian cancer are just over 22% and 10%, respectively [Ries L et al. National Cancer Institute: SEER Program 2007]. For unstaged ovarian cancer, the survival rate is just over 20%. This article presents information on 2 algorithms currently approved by the Food and Drug Administration to improve identification of high-risk women with the goal of triaging these women to optimal care.</style></abstract><number><style face="normal" font="default" size="100%">7</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>